Ra Capital Management, L.P. Sells 45,923 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 45,923 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $0.37, for a total transaction of $16,991.51. Following the completion of the sale, the insider directly owned 378,666 shares of the company’s stock, valued at approximately $140,106.42. The trade was a 10.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.38, for a total transaction of $99,751.14.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total transaction of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Stock Up 8.0%

Shares of NASDAQ:HOWL traded up $0.03 during trading on Thursday, reaching $0.39. 805,388 shares of the company traded hands, compared to its average volume of 538,108. The company’s 50 day moving average is $0.67 and its two-hundred day moving average is $0.72. The firm has a market capitalization of $19.16 million, a PE ratio of -0.32 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 52 week low of $0.36 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. As a group, research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Large investors have recently modified their holdings of the business. Regal Investment Advisors LLC raised its holdings in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after purchasing an additional 221,766 shares during the last quarter. Susquehanna International Group LLP raised its holdings in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in Werewolf Therapeutics during the 3rd quarter worth approximately $304,000. Institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on HOWL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Werewolf Therapeutics has an average rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.